Data from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase Ii Nrg-Gy023 Trial
AuthID
P-019-2YX
P-019-2YX